Form 4: Immunovant's Chief Medical Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Michael Geffner, Immunovant's Chief Medical Officer, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On October 23, 2024, Michael Geffner, the Chief Medical Officer of Immunovant, Inc., sold 3,189 shares of common stock at a weighted average price of $29.53 per share.
- The sale was mandated by Immunovant to cover tax withholding obligations associated with the vesting of 6,250 restricted stock units (RSUs) on October 17, 2024, which were part of a grant of 100,000 RSUs on January 17, 2023.
- Following the transaction, Geffner directly owns 134,971 shares of Immunovant common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sell to cover taxes) and doesn't provide any strong positive or negative signals about the company's performance or future prospects.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives. This transaction is not necessarily indicative of the executive's sentiment towards the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| January 17, 2023 | Grant date of 100,000 restricted stock units (RSUs). |
| October 17, 2024 | Vesting date of 6,250 RSUs. |
| October 23, 2024 | Date of stock sale to cover tax obligations. |
| October 25, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.